Related references
Note: Only part of the references are listed.Risk factors for community-onset urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli
Turkan Tuzun et al.
TURKISH JOURNAL OF MEDICAL SCIENCES (2019)
Proton pump inhibitor use as a risk factor for Enterobacteriaceal infection: a case-control study
R. Cunningham et al.
JOURNAL OF HOSPITAL INFECTION (2018)
Proton Pump Inhibitor Use Is Associated With Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Rectal Carriage at Hospital Admission: A Cross-Sectional Study
Pepijn Huizinga et al.
CLINICAL INFECTIOUS DISEASES (2017)
Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population
Marlies Mulder et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Risk factors for extended-spectrum β-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: a case-control study
M. Sogaard et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
Proton pump inhibitors alter the composition of the gut microbiota
Matthew A. Jackson et al.
GUT (2016)
Proton pump inhibitors and gastroenteritis
Robert-Jan Hassing et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2016)
Community-Onset Escherichia coli Infection Resistant to Expanded-Spectrum Cephalosporins in Low-Prevalence Countries
Benjamin A. Rogers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Service evaluation of selected risk factors for extended-spectrum beta-lactamase Escherichia coli urinary tract infections: a case-control study
T. Inns et al.
JOURNAL OF HOSPITAL INFECTION (2014)
Community-Associated Extended-Spectrum β-Lactamase-Producing Escherichia coli Infection in the United States
Yohei Doi et al.
CLINICAL INFECTIOUS DISEASES (2013)
Risk Factors for Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Enterobacteriaceae -A Case-Control Study in a Low Prevalence Country
Arne Soraas et al.
PLOS ONE (2013)
Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection
C. Bavishi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
A Multinational Survey of Risk Factors for Infection with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Nonhospitalized Patients
Ronen Ben-Ami et al.
CLINICAL INFECTIOUS DISEASES (2009)
Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli
Jesus Rodriguez-Bano et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin
C Washington et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2006)
Mechanisms of disease:: The new β-lactamases
GA Jacoby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients
R Colodner et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2004)
Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat
PA Bradford
CLINICAL MICROBIOLOGY REVIEWS (2001)
Share Paper
